BindingDB logo
myBDB logout

67 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
24582476 17 cis-1-Oxo-heterocyclyl-4-amido cyclohexane derivatives as NPY5 receptor antagonists.EBI Lundbeck Research USA, Inc.
24365162 126 Ligands of the neuropeptide Y Y2 receptor.EBI The Scripps Research Institute
24900634 36 Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.EBI University of Copenhagen
24074877 135 Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.EBI University of Regensburg
24090364 96 Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.EBI University of Regensburg
21074426 34 The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.EBI GlaxoSmithKline
20951033 59 Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.EBI GlaxoSmithKline
20813523 26 Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.EBI GlaxoSmithKline SpA
22445286 19 Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.EBI Pfizer Inc.
22361135 29 Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists.EBI Lundbeck Research USA
18160282 40 Discovery of novel orally active ureido NPY Y5 receptor antagonists.EBI Schering-Plough Research Institute
16002290 66 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.EBI Taisho Pharmaceutical Co. Ltd.
10698438 12 N-(sulfonamido)alkyl[tetrahydro-1H-benzo[e]indol-2-yl]amines: potent antagonists of human neuropeptide Y Y5 receptor.EBI The R. W. Johnson Pharmaceutical Research Institute
21924902 43 5-(2'-Pyridyl)-2-aminothiazoles: alkyl amino sulfonamides and sulfamides as potent NPY(5) antagonists.EBI Lundbeck Research USA, Inc.
21782428 61 Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.EBI Lundbeck Research USA, Inc.
21782430 26 N-Heteroaryl glycinamides and glycinamines as potent NPY5 antagonists.EBI Lundbeck Research USA, Inc.
19616955 34 Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.EBI Tsukuba Research Institute
21493077 39 Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.EBI Universit£t Regensburg
21295475 21 Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.EBI Pfizer Inc.
20630754 33 Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.EBI GlaxoSmithKline
19864135 43 Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.EBI Schering Plough Research Institute
19720539 32 Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.EBI Tsukuba Research Institute
19679469 26 Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.EBI Tsukuba Research Institute
19640706 25 Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.EBI Tsukuba Research Institute
19525116 43 Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.EBI Tsukuba Research Institute
19581086 37 The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.EBI GlaxoSmithKline
19464889 43 Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.EBI Tsukuba Research Institute
19459652 56 Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.EBI Tsukuba Research Institute
19243937 26 Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.EBI Tsukuba Research Institute
19233647 35 Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.EBI Tsukuba Research Institute
19053784 19 Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.EBI University of Regensburg
18752943 36 Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.EBI Banyu Tsukuba Research Institute
18723347 59 Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.EBI Banyu Tsukuba Research Institute
18637668 38 (9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.EBI Tsukuba Research Institute
17425299 8 Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.EBI Bayer Pharmaceuticals Corporation
17292607 12 A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.EBI Bayer Pharmaceuticals Corporation
17055726 68 Identification of selective neuropeptide Y2 peptide agonists.EBI Bayer Pharmaceuticals Corporation
15863317 45 Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.EBI Taisho Pharmaceutical Co. Ltd
15109631 86 Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.EBI Novartis Pharma AG
14741250 29 Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y(5) antagonists.EBI Universidad de Navarra
14505677 28 Structure-activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists.EBI Pfizer Global Research and Development
12781180 24 Structure-activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres.EBI Pfizer Global Research and Development
12593645 2 In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.EBI Pfizer Inc.
12593644 27 Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of neuropeptide Y5 receptor antagonists.EBI Tsukuba Research Institute
12139462 34 Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.EBI AstraZeneca
12067558 15 High-throughput synthesis optimization of sulfonamide NPY Y5 antagonists.EBI Lundbeck Research USA, Inc.
12067557 24 Discovery of potent and selective small molecule NPY Y5 receptor antagonists.EBI Lundbeck Research USA, Inc.
11934581 32 Novel potent antagonists of human neuropeptide Y Y5 receptor. Part 1: 2-oxobenzothiazolin-3-acetic acid derivatives.EBI Fujisawa Pharmaceutical Co., Ltd.
11909705 19 Novel potent antagonists of human neuropeptide Y-Y5 receptor. Part 4: tetrahydrodiazabenzazulene derivatives.EBI Fujisawa Pharmaceutical Co., Ltd.
11859006 15 Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives.EBI Fujisawa Pharmaceutical Co., Ltd.
11858996 32 Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives.EBI Fujisawa Pharmaceutical Co., Ltd.
11527716 29 Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.EBI The R. W. Johnson Pharmaceutical Research Institute
11527715 33 Aminopyrazoles with high affinity for the human neuropeptide Y5 receptor.EBI The R. W. Johnson Pharmaceutical Research Institute
11428928 70 Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.EBI Amgen Inc.
11334558 42 Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).EBI University of Cincinnati and VA Medical Centers
11063624 95 Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.EBI Amgen, Inc.
10937714 19 N-acylated alpha-(3-pyridylmethyl)-beta-aminotetralin antagoinists of the human neuropeptide Y Y5 receptor.EBI The R. W. Johnson Pharmaceutical Research Institute
10915060 54 Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.EBI University of Regensburg
10866375 50 Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.EBI Novartis Pharma AG
10669561 23 alpha-Substituted N-(sulfonamido)alkyl-beta-aminotetralins: potent and selective neuropeptide Y Y5 receptor antagonists.EBI The R. W. Johnson Pharmaceutical Research Institute
9925722 18 Pharmacological treatment of obesity: therapeutic strategies.EBI The R. W. Johnson Pharmaceutical Research Institute
9371234 49 Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.EBI Lilly Research Laboratories
27524297 212 A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.BDB Massachusetts Institute of Technology